Tweet Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. Gold R, Selmaj KW, Berkovich R, Cohen JA, Comi G, Havrdová EK, Sheffield JK, Desai H, Cheng CY, Riolo JV, Thorpe A, DeBoer E, Cree BAC.Ann Clin Transl Neurol. 2026 Mar 27. doi: 10.1002/acn3.70366. Online…
Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the…
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like…